ATHO
Asset Logo

Alterity Therapeutics Limited

๐Ÿ‡ฆ๐Ÿ‡บ ASX

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

N/A
Growth

10 months growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

1
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

Alterity Therapeutics Limited - Option Expiring 31-Aug-2026

๐Ÿ“ˆ Performance

Price History

0.00%

1M

All Time

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.00

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in ATHO

1

๐Ÿ“Š Total Capital Earnings

N/A

๐Ÿ”ƒ Average investment frequency

N/A

๐Ÿ’ต Average investment amount

N/A

โฐ Last time a customer invested in ATHO

N/A
ATHO investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

100%

Less than 50k

๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

35 - 90

100%
๐Ÿ™‹ Legal gender of investors

Female

Male

100%

Pearlers who invest in ATHO also invest in...

Audinate Group Limited

AD8

Audinate Group Ltd. engages in the development and commercialization of audio visual software and hardware. Its principal activity is the development and sale of digital AV networking solutions. Its products include Dante AVIO adapters, software, Dante-enabled products, solutions for manufacturers and solutions for software developers. Dante is a technology platform that distributes digital audio and video signals over computer networks. Dante comprises software and chips, cards and modules that are sold to and integrated inside the AV products of its original equipment manufacturer (OEM) customers. The company also provides a series of products and services for AV professionals, including AVIO adapters and management and control software. Dante replaces all of those connections with a computer network, sending video or hundreds of channels of audio over slender ethernet cables with digital fidelity. Dante is available in over 3,500 products from more than 500 manufacturers.

๐Ÿ™Œ Performance (5Yr p.a)

4.50%

๐Ÿ“Š Share price

$9.25 AUD

๐Ÿ”จ COMMERCIAL SERVICES & SUPPLIES

Find Out More

ANZ Group Holdings Ltd. operates as a non-operating holding company. The company operates in six divisions: Australia Retail, Australia Commercial, Institutional, New Zealand, Pacific, and Group Center. The Australia Retail division offers a range of banking services, such as home loans, deposits, credit cards and personal loans. The company also offers digital and Internet banking and phone banking. The Australia Commercial division provides a full range of banking products and financial services, including asset financing, across customer segments: small business owners and medium commercial customers. The Institutional division services government, global institutional and corporate customers across Australia, New Zealand and International. The New Zealand division provides personal banking and wealth management services. The Pacific division provides retail products for traditional relationship banking. The Group center supports the operating divisions, including technology, property, and risk management.

๐Ÿ™Œ Performance (5Yr p.a)

4.16%

๐Ÿ“Š Share price

$31.10 AUD

๐Ÿ’ฐ HIGH DIVIDEND

โš–๏ธ HIGH GOVERNANCE

๐Ÿฆ BANKING

Calix Ltd. engages in the development of patent-protected, platform technology that produces new materials and processes to solve global challenges. The company is headquartered in Pymble, New South Wales and currently employs 129 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in solving global challenges in industrial decarbonization and sustainability. Its segments include Leilac (a CO2 mitigation business), Sustainable Processing, Advanced Batteries and Magnesia. The Leilac segment is accelerating the transition to net-zero by providing the most compelling decarbonization solution for global cement and lime. The Sustainable Processing segment enables mineral processing to enter the electric age with applications targeting green iron and steel, zero emissions alumina, and sustainable lithium and other critical minerals. The Advanced Batteries segment is focused on the development of cathode materials. Magnesia segment offers safe and sustainable magnesium-based products solving global environmental challenges in water and agriculture. In addition, it develops and commercializes applications for antimicrobial resistance and sustainable processing of magnesium metal.

๐Ÿ™Œ Performance (5Yr p.a)

2.96%

๐Ÿ“Š Share price

$0.81 AUD

๐Ÿงช CHEMICALS

Carnegie Clean Energy Ltd. engages in the development and ownership of the patented CETO wave energy technology. The firm is the owner and developer of the CETO and MoorPower technologies, which capture energy from ocean waves and convert it into electricity. CETO is its core wave energy technology, a submerged point absorber type wave energy converter which converts ocean waves into zero-emission electricity. MoorPower is a CETO derived wave energy technology designed to deliver a sustainable energy supply for marine industries operating at a fixed moored location, reducing the reliance on diesel. The Mooring Tensioner is a component which provides passive tension required for rotary electric power take-off systems, such as is required for CETO and MoorPower. Its projects include ACHIEVE Programme, MoorPower Scaled Demonstrator, Garden Island Microgrid, Microsoft AI for Earth project, CETO Next Generation and others.

๐Ÿ™Œ Performance (5Yr p.a)

780.00%

๐Ÿ“Š Share price

$0.04 AUD

๐Ÿ”‹ UTILITIES

ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.

๐Ÿ™Œ Performance (5Yr p.a)

9.76%

๐Ÿ“Š Share price

$9.82 AUD

๐Ÿ“ˆ HIGH PRICE GROWTH

๐Ÿ‡ฆ๐Ÿ‡บ EX AUSTRALIA

Want more shares? Try these...

PT Aneka Tambang Tbk engages in the exploration, exploitation, processing, refining, and marketing of minerals, precious metals, and coal. The company is headquartered in Jakarta Selatan, Dki Jakarta and currently employs 3,791 full-time employees. The company is engaged in the business of mining various types of minerals, and of mining-related industry, trade, transportation, and mining sector services. The firm operates through three segments: Nickel, Precious Metals and Refinery, and Bauxite and Alumina. Its Nickel segment is comprised of ferronickel and nickel ore sales. Its Precious Metals and Refinery business segment consists of gold commodity, silver and precious metals processing and refinery services. Its gold ore mining is produced from two mining sites: Pongkor, West Java and Cibaliung, Banten. Bauxite contains alumina (AI203) and a mixture of silica, various iron oxides, and titanium dioxide. The company has three ferronickel smelters (FeNi II, III and IV) with four production lines with annual combined capacity of 27,000 TNi. The Company, through its subsidiary, PT Indonesia Coal Resources, produces coal from the Sarolangun coal mine located in Jambi Province, Indonesia.

๐Ÿ™Œ Performance (5Yr p.a)

-1.00%

๐Ÿ“Š Share price

$0.95 AUD

โ›๏ธ MINING

๐Ÿ•Š๏ธ SOCIALLY AWARE

๐Ÿƒ HIGH ESG SCORE

๐ŸŒณ ENVIRONMENTAL

ATOM.AX was created on 2022-12-07 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Global Uranium & Nuclear Components Total Return Index

๐Ÿ“Š Share price

$15.49 AUD

โšก๏ธ ENERGY

Articore Group Ltd. engages in the development and provision of online marketplace, where artists upload their designs and creative works. These marketplaces facilitate artistsโ€™ design and sale of a range of products printed with the artistsโ€™ artwork to their customers worldwide. The products are produced and shipped by third party service providers, such as product manufacturers, printers and shipping companies referred to as fulfillers. The firm sells uncommon designs, everyday products, such as apparel, stationery, housewares, bags, and wall arts. The company operates through two segments: Redbubble and TeePublic. Redbubble and TeePublic segments are online marketplace for print on demand products. Redbubble product range includes clothing, stickers, phone cases, wall art, home & living, kids and babies, accessories, stationery and office, and gifts. TeePublic is a marketplace for independent creators to sell the merchandise bearing their art.

๐Ÿ™Œ Performance (5Yr p.a)

-16.75%

๐Ÿ“Š Share price

$0.31 AUD

๐Ÿ›๏ธ CONSUMER

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 11 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

๐Ÿ™Œ Performance (5Yr p.a)

-17.69%

๐Ÿ“Š Share price

$0.00 AUD

๐Ÿงฌ BIOTECHNOLOGY

Compare
Add to watchlist